Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 3, 2011, Pages 800-807

  Rose, Brent S ^a   Aydogan, Bulent ^b   Liang, Yun ^a   Yeginer, Mete ^b   Hasselle, Michael D ^b   Dandekar, Virag ^b   Bafana, Rounak ^c   Yashar, Catheryn M ^a   Mundt, Arno J ^a   Roeske, John C ^d   Mell, Loren K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Bone marrow; Cervical cancer; Hematologic toxicity; Normal tissue complication probability

Indexed keywords

BODY MASS INDEX; BONE MARROW; CERVICAL CANCER; CERVICAL CANCERS; CHEMORADIOTHERAPY; CONCURRENT CISPLATIN; DOSIMETRIC PARAMETER; DOSIMETRIC PLANNING; HEMATOLOGIC TOXICITY; LINEAR MODELING; LINEAR REGRESSION MODELS; NEGATIVE CORRELATION; NORMAL TISSUE COMPLICATION PROBABILITIES; NORMAL-TISSUE COMPLICATION PROBABILITY MODELS; PELVIC BONE; PELVIC RADIOTHERAPY; RECEIVER OPERATING CHARACTERISTIC CURVES; REGRESSION COEFFICIENT; WHITE BLOOD CELLS;

BLOOD; BONE; CELLS; DOSIMETERS; DOSIMETRY; LINEAR REGRESSION; PATIENT MONITORING; PLATINUM COMPOUNDS; PROBABILITY; TOXICITY;

DISEASES;

CISPLATIN;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HYPOTHESIS; LEUKOCYTE COUNT; LEUKOPENIA; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE; STATISTICAL MODEL; THROMBOCYTOPENIA; TREATMENT PLANNING; UTERINE CERVIX CANCER; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BONE MARROW; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEMOGLOBIN A; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; MODELS, STATISTICAL; NEUTROPHILS; ORGANS AT RISK; PELVIS; PLATELET COUNT; PROBABILITY; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; UTERINE CERVICAL NEOPLASMS;

EID: 79551503325     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.11.010     Document Type: Article

References (42)

1. H.M. Keys, B.N. Bundy, and F.B. Stehman Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 340 1999 1154 1161
2. P.G. Rose, B.N. Bundy, and E.B. Watkins Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 1999 1144 1153
3. M. Morris, P.J. Eifel, and J. Lu Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 340 1999 1137 1143
4. P.J. Eifel, K. Winter, and M. Morris Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of Radiation Therapy Oncology Group trial 90-01 J Clin Oncol 22 2004 872 880
5. C.W. Whitney, W. Sause, and B.N. Bundy Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to RT in stage IIB-IVA carcinoma of the cervix J Clin Oncol 17 1999 1339 1348
6. W.A. Peters, P.Y. Liu, and R.J. Barrett Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix J Clin Oncol 18 2000 1606 1613
7. J.A. Green, J.M. Kirwan, and J.F. Tierney Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix Lancet 358 2001 781 786
8. M.A. Torres, A. Jhingran, and H.D. Thames Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment Int J Radiat Oncol Biol Phys 70 2008 118 125
9. N.R. Abu-Rustum, S. Lee, and A. Correa Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer Gynecol Oncol 81 2001 88 91
10. K. Parker, E. Gallop-Evans, and L. Hanna Five years experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 74 2009 140 146
11. R.M. Lanciano, T.F. Pajak, and K. Martz The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation Int J Radiat Oncol Biol Phys 25 1993 391 397
12. C.A. Perez, P.W. Grigsby, and H. Castro-Vita Carcinoma of the uterine cervix: Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of RT Int J Radiat Oncol Biol Phys 32 1995 1275 1288
13. R.E. Ellis The distribution of active bone marrow in the adult Phys Med Biol 5 1961 255 258
14. P. Mauch, L. Constine, and J. Greenberger Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy Int J Radiat Oncol Biol Phys 31 1995 1319 1339
15. E. Hall, and A. Giaccia Clinical response of normal tissues E.J. Hall, A.J. Giaccia, Radiobiology for the radiologist 6th ed 2006 Lippincott Williams & Wilkins Philadelphia 333 337 461-332
16. L.K. Mell, J.D. Kochanski, and J.C. Roeske Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy Int J Radiat Oncol Biol Phys 66 2006 1356 1365
17. L.K. Mell, D.A. Schomas, and J.K. Salama Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and IMRT Int J Radiat Oncol Biol Phys 70 2008 1431 1437
18. S. Mutyala, N. Thawani, and J.M. Vainshtein Dose constraint recommendations and a predictive nomogram of incidence of hematological toxicity for cervix cancer patients treated with concurrent cisplatin and IMRT [Abstract] Int J Radiat Oncol Biol Phys 72 2008 S359 S360
19. D.T. Giangreco, K. Albuquerque, and J. Norton Predictors of hematologic toxicity and implications for bone-marrow sparing pelvic IMRT for cervical cancer [Abstract] Int J Radiat Oncol Biol Phys 69 2007 S399
20. L.K. Mell, H. Tiryaki, and K.H. Ahn Dosimetric comparison of bone marrow-sparing IMRT versus conventional techniques for treatment of cervical cancer Int J Radiat Oncol Biol Phys 71 2008 1504 1510
21. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer Int J Radiat Oncol Biol Phys 31 1995 1341 1346
22. V. Blomlie, E.K. Rofstad, and A. Skjonsberg Female pelvic bone marrow: Serial MR imaging before, during, and after RT Radiology 194 1995 537 543
23. L.F. Fajardo, M. Berthrong, and R.E. Anderson Hematopoietic tissue L.F. Fajardo, M. Berthrong, R.E. Anderson, Radiation pathology 2001 Oxford University Press Oxford 379 388
24. P. Rubin, S. Landman, and E. Mayer Bone marrow regeneration and extension after extended field irradiation in Hodgkins disease Cancer 32 1973 699 711
25. E.L. Sacks, M.L. Goris, and E. Glatstein Bone marrow regeneration following large field radiation: Influence of volume, age, dose, and time Cancer 42 1978 1057 1065
26. C.W. Scarantino, P. Rubin, and L.S. Constine The paradoxes in patterns and mechanism of bone marrow regeneration after irradiation Radiother Oncol 2 1984 215 225
27. R. Pearcey, M. Brundage, and P. Drouin Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix J Clin Oncol 20 2002 966 972
28. T.A. Gatcliffe, K.S. Tewari, and A. Shah A feasibility study of topotecan with standard-dose cisplatin and concurrent primary RT in locally advanced cervical cancer Gynecol Oncol 112 2009 85 89
29. A. Dueñas-Gonzalez, L. Cetina-Perez, and C. Lopez-Graniel Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer Int J Radiat Oncol Biol Phys 61 2005 817 823
30. A.J. Mundt, J. Rotmensch, and S.E. Waggoner Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies Gynecol Oncol 92 2004 801 805
31. J. Petera, K. Odrazka, and T. Frgala External beam radiotherapy and high-dose brachytherapy combined with cisplatin and paclitaxel in patients with advanced cervical carcinoma Gynecol Oncol 99 2005 334 338
32. H.J. Long, B.N. Bundy, and E.C. Grendys Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix J Clin Oncol 23 2005 4626 4633
33. D.H. Moore, J.A. Blessing, and R.P. McQuellon Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix J Clin Oncol 22 2004 3113 3119
34. C.J. Brixey, J.C. Roeske, and A.E. Lujan Impact of IMRT on acute hematologic toxicity in women with gynecologic malignancies Int J Radiat Oncol Biol Phys 54 2002 1388 1396
35. A.J. Mundt, and J.C. Roeske Can IMRT replace brachytherapy in the management of cervical cancer? Counterpoint Brachytherapy 1 2002 192 194
36. M.T. Milano, A.B. Jani, and K.J. Farrey Intensity-modulated radiation therapy in the treatment of anal cancer: Toxicity and clinical outcome Int J Radiat Oncol Biol Phys 63 2005 354 361
37. Liang Y, Messer K, Rose BS, et al. The impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data. Int J Radiat Oncol Biol Phys. In press.
38. R.J. Hartsock, E.B. Smith, and C.S. Petty Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest Am J Clin Pathol 43 1965 326 331
39. J.B. Vogler, and W.A. Murphy Bone marrow imaging Radiology 168 1988 679 693
40. S. Basu, M. Houseni, and G. Bural Magnetic resonance imaging based bone marrow segmentation for quantitative calculation of pure red marrow metabolism using 2-deoxy-2-[F-18]fluoro-D-glucose-PET Mol Imaging Biol 9 2007 361 365
41. J.C. Roeske, and A.J. Mundt Incorporation of MRI into intensity modulated whole-pelvic radiation treatment to reduce the volume of pelvic bone marrow irradiated Int Congr Ser 2004 307 312
42. J.C. Roeske, A. Lujan, and R.C. Reba Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic RT treatment planning for gynecologic malignancies Radiother Oncol 77 2005 11 17